SCHEMBL1542760

SCHEMBL1542760

COc1c(C(=O)Nc2cccc(CNS(C)(=O)=O)c2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.55
NFATC1 O95644 2/20 0.46
NR1H4 Q96RI1 5/20 0.39
KCNA5 P22460 1/20 0.37
PARP1 P09874 1/20 0.36
ROCK2 O75116 1/20 0.36
ROCK1 Q13464 1/20 0.36
PPARG P37231 2/20 0.35
PPARA Q07869 2/20 0.35
PPARD Q03181 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
ABL1 P00519 1/20 0.35
GAA P10253 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
SENP5 Q96HI0 1/20 0.34
SENP2 Q9HC62 1/20 0.34
SENP1 Q9P0U3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543035 0.92 CYP3A4 (0.61) CYP3A4NFATC1NR1H4ABL1GAA
SCHEMBL1542874 0.88 CYP3A4 (0.51) CYP3A4NR1H4PARP1PPARGPPARA
SCHEMBL1542683 0.87 CYP3A4 (0.61) CYP3A4NR1H4ABL1GAAKDM4E
SCHEMBL1542466 0.87 CYP3A4 (0.54) CYP3A4NFATC1NR1H4ROCK2ROCK1
SCHEMBL1359885 0.85 NFATC1 (0.45) CYP3A4NFATC1NR1H4KCNA5PARP1
SCHEMBL1542824 0.83 CYP3A4 (0.52) CYP3A4NR1H4ABL1GAAKDM4E
SCHEMBL1542666 0.81 CYP3A4 (0.56) CYP3A4NR1H4CD274ABL1GAA
SCHEMBL2128170 0.79 CYP3A4 (0.53) CYP3A4NR1H4ABL1KDM4EMAPT
SCHEMBL1542439 0.79 CYP3A4 (0.51) CYP3A4ROCK2ROCK1KDM4EHSD17B10
SCHEMBL1542202 0.78 CYP3A4 (0.60) CYP3A4CD274ABL1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP disclosed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP disclosed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885NFATC1 1103/4885NR1H4 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.